Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

Maze Therapeutics, Inc., (MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines, has priced its initial public offering or IPO of 8.8 million ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

A dozen hedge funds, including Perceptive, Farallon, and Marshall Wace, will benefit from companies that either went public ...

and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Maze, backed by healthcare venture firms ARCH Venture and Third Rock Ventures, as well as ...

Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic Kidney Disease Drugs Drugs currently used to ...

More on Renaissance Capital Greenwich Funds - Renaissance IPO ETF, Maze Therapeutics, Inc., etc. Maze Therapeutics Seeks IPO For Trials Ramp-Up IPO: Favorable Capital Markets In 2025 Not Yet A ...